Mizuho Securities Sticks to Its Buy Rating for Magenta Therapeutics (MGTA)

In a report released today, Vamil Divan from Mizuho Securities maintained a Buy rating on Magenta Therapeutics (MGTAResearch Report), with a price target of $8.00. The company’s shares closed last Thursday at $2.24.

According to, Divan is a 2-star analyst with an average return of 0.6% and a 50.8% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on Magenta Therapeutics is a Strong Buy with an average price target of $7.00.

See the top stocks recommended by analysts >>

Magenta Therapeutics’ market cap is currently $141.7M and has a P/E ratio of -1.85.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.

Read More on MGTA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More